At the AGM of January 18th, Avacta reported good progress for both the Affimer therapeutic and reagents programs. Their lead immuno-oncology development program is proceeding according to plan and multiple development milestones are expected in the course of 2018 (see next section for further details).
23 Jan 2018
Avacta Group Plc - Capital Network: On track and undervalued
Sign up for free to access
Get access to the latest equity research in real-time from 12 commissioned providers.
Get access to the latest equity research in real-time from 12 commissioned providers.
Avacta Group Plc - Capital Network: On track and undervalued
Avacta Group PLC (AVCT:LON) | 44.8 0.1 0.3% | Mkt Cap: 156.9m
- Published:
23 Jan 2018 -
Author:
Dr. Riccardo Lowi -
Pages:
5
At the AGM of January 18th, Avacta reported good progress for both the Affimer therapeutic and reagents programs. Their lead immuno-oncology development program is proceeding according to plan and multiple development milestones are expected in the course of 2018 (see next section for further details).